FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313644672> ?p ?o ?g. }

• W4313644672 abstract "Abstract Purpose To determine the maximum tolerated dose (MTD) of autologous chimeric antigen receptor T cells (HER2-CART) after lymphodepletion and to describe the cellular kinetics, safety, feasibility of repeat treatment cycles, and antitumor activity of HER2-CART in patients with advanced sarcoma. Patients and Methods On this phase I study, 13 patients with progressive, metastatic HER2+ sarcoma were treated in 14 enrollments; one patient who achieved complete remission was re-enrolled because of disease recurrence. Lymphodepletion consisted of fludarabine (Flu) 25 mg/m2/dose x 5 days with or without cyclophosphamide (Cy) 30 mg/kg/dose x 2 days. The dose cohorts evaluated include 1x108 total T-cells/m2 after Flu (cohort A); 1x108 total T-cells/m2 after Flu/Cy (cohort B) and 1x108 CAR-positive T-cells/m2 after Flu/Cy (cohort C). The evaluation of safety was the primary endpoint. Secondary outcomes included assessment of cellular kinetics and antitumor activity. Results All study participants received at least one infusion of HER2-CART after lymphodepletion and were included in the analysis (median age 14 years; range 4-55 years). Seven received multiple HER2-CART infusions. CART expansion was observed after all but two of 21 total infusions given after lymphodepletion. Nine of 12 (75%) patients in cohorts A and B developed grade 1-2 CRS. Two patients in cohort C experienced dose limiting toxicity (DLT) with grade 3-4 CRS. All patients recovered from treatment-related adverse events during study follow-up. Median OS was 8.2 months (95% CI, 4.4-17 months). Antitumor activity was observed at the MTD (cohort B), with 1-year OS and PFS of 62.5% (95% CI, 22.9%-86.1%) and 33.3% (95% CI, 7.8-62.3%), respectively. Three patients remain alive, with one in long-term remission at the sixth year of follow-up. While infused CART products did not exhibit a distinct immunophenotype by sarcoma histology, we observed different trends in expression of immune checkpoints when compared by disease and by treatment response. Conclusion and Relevance: Autologous HER2-CART can be infused safely after lymphodepletion in patients with progressive sarcoma, and the preliminary evidence of antitumor activity observed supports testing their efficacy in a phase II trial. Trial Registration: ClinicalTrials.gov identifier: NCT00902044" @default.
• W4313644672 created "2023-01-07" @default.
• W4313644672 creator A5000112687 @default.
• W4313644672 creator A5000490817 @default.
• W4313644672 creator A5001808348 @default.
• W4313644672 creator A5001837533 @default.
• W4313644672 creator A5002405692 @default.
• W4313644672 creator A5006453605 @default.
• W4313644672 creator A5007141702 @default.
• W4313644672 creator A5009631835 @default.
• W4313644672 creator A5009968414 @default.
• W4313644672 creator A5015415077 @default.
• W4313644672 creator A5021029688 @default.
• W4313644672 creator A5022024359 @default.
• W4313644672 creator A5022938948 @default.
• W4313644672 creator A5027058968 @default.
• W4313644672 creator A5027578451 @default.
• W4313644672 creator A5029569800 @default.
• W4313644672 creator A5029941019 @default.
• W4313644672 creator A5032050779 @default.
• W4313644672 creator A5039084091 @default.
• W4313644672 creator A5041972709 @default.
• W4313644672 creator A5045336996 @default.
• W4313644672 creator A5052162946 @default.
• W4313644672 creator A5056053037 @default.
• W4313644672 creator A5056105964 @default.
• W4313644672 creator A5056402774 @default.
• W4313644672 creator A5058287032 @default.
• W4313644672 creator A5059406196 @default.
• W4313644672 creator A5059562009 @default.
• W4313644672 creator A5060218074 @default.
• W4313644672 creator A5068795319 @default.
• W4313644672 creator A5077489156 @default.
• W4313644672 creator A5083939310 @default.
• W4313644672 creator A5087257662 @default.
• W4313644672 date "2023-01-06" @default.
• W4313644672 modified "2023-10-14" @default.
• W4313644672 title "Autologous HER2-specific CAR T-cells after lymphodepletion for advanced sarcoma" @default.
• W4313644672 doi "https://doi.org/10.21203/rs.3.rs-2409436/v1" @default.
• W4313644672 hasPublicationYear "2023" @default.
• W4313644672 type Work @default.
• W4313644672 citedByCount "0" @default.
• W4313644672 crossrefType "posted-content" @default.
• W4313644672 hasAuthorship W4313644672A5000112687 @default.
• W4313644672 hasAuthorship W4313644672A5000490817 @default.
• W4313644672 hasAuthorship W4313644672A5001808348 @default.
• W4313644672 hasAuthorship W4313644672A5001837533 @default.
• W4313644672 hasAuthorship W4313644672A5002405692 @default.
• W4313644672 hasAuthorship W4313644672A5006453605 @default.
• W4313644672 hasAuthorship W4313644672A5007141702 @default.
• W4313644672 hasAuthorship W4313644672A5009631835 @default.
• W4313644672 hasAuthorship W4313644672A5009968414 @default.
• W4313644672 hasAuthorship W4313644672A5015415077 @default.
• W4313644672 hasAuthorship W4313644672A5021029688 @default.
• W4313644672 hasAuthorship W4313644672A5022024359 @default.
• W4313644672 hasAuthorship W4313644672A5022938948 @default.
• W4313644672 hasAuthorship W4313644672A5027058968 @default.
• W4313644672 hasAuthorship W4313644672A5027578451 @default.
• W4313644672 hasAuthorship W4313644672A5029569800 @default.
• W4313644672 hasAuthorship W4313644672A5029941019 @default.
• W4313644672 hasAuthorship W4313644672A5032050779 @default.
• W4313644672 hasAuthorship W4313644672A5039084091 @default.
• W4313644672 hasAuthorship W4313644672A5041972709 @default.
• W4313644672 hasAuthorship W4313644672A5045336996 @default.
• W4313644672 hasAuthorship W4313644672A5052162946 @default.
• W4313644672 hasAuthorship W4313644672A5056053037 @default.
• W4313644672 hasAuthorship W4313644672A5056105964 @default.
• W4313644672 hasAuthorship W4313644672A5056402774 @default.
• W4313644672 hasAuthorship W4313644672A5058287032 @default.
• W4313644672 hasAuthorship W4313644672A5059406196 @default.
• W4313644672 hasAuthorship W4313644672A5059562009 @default.
• W4313644672 hasAuthorship W4313644672A5060218074 @default.
• W4313644672 hasAuthorship W4313644672A5068795319 @default.
• W4313644672 hasAuthorship W4313644672A5077489156 @default.
• W4313644672 hasAuthorship W4313644672A5083939310 @default.
• W4313644672 hasAuthorship W4313644672A5087257662 @default.
• W4313644672 hasBestOaLocation W43136446721 @default.
• W4313644672 hasConcept C126322002 @default.
• W4313644672 hasConcept C127413603 @default.
• W4313644672 hasConcept C141071460 @default.
• W4313644672 hasConcept C197934379 @default.
• W4313644672 hasConcept C203092338 @default.
• W4313644672 hasConcept C2776694085 @default.
• W4313644672 hasConcept C2776755627 @default.
• W4313644672 hasConcept C2777275308 @default.
• W4313644672 hasConcept C2779263901 @default.
• W4313644672 hasConcept C29730261 @default.
• W4313644672 hasConcept C535046627 @default.
• W4313644672 hasConcept C71924100 @default.
• W4313644672 hasConcept C72563966 @default.
• W4313644672 hasConcept C78519656 @default.
• W4313644672 hasConcept C90924648 @default.
• W4313644672 hasConceptScore W4313644672C126322002 @default.
• W4313644672 hasConceptScore W4313644672C127413603 @default.
• W4313644672 hasConceptScore W4313644672C141071460 @default.
• W4313644672 hasConceptScore W4313644672C197934379 @default.
• W4313644672 hasConceptScore W4313644672C203092338 @default.
• W4313644672 hasConceptScore W4313644672C2776694085 @default.
• W4313644672 hasConceptScore W4313644672C2776755627 @default.
• W4313644672 hasConceptScore W4313644672C2777275308 @default.

• next